Song Suk-Heung, Jeong Sehoon
Ginkgo Bioworks Inc., Boston, MA, USA.
Department of Artificial Intelligence and Data Science, Sejong University, Seoul, Republic of Korea.
Clin Exp Reprod Med. 2024 Sep 20. doi: 10.5653/cerm.2024.06954.
Modern drug discovery is driven by high demand in the pharmaceutical industry to test growing libraries of compounds against potential targets. High-throughput screening (HTS) is characterized by fully automated experimentation that leverages robotic liquid handling systems, analytical techniques, and advanced computing and statistics, including the recent integration of artificial intelligence. To align with this trend, it is crucial to develop and implement new HTS platforms that offer improved predictivity and physiological relevance. In recent years, microphysiological systems, commonly known as organ-on-chip (OoC) systems, have progressed from a theoretical concept to a powerful alternative to conventional in vitro and animal models. High-throughput OoC (HT-OoC) systems could represent the disruptive technology sought by pharmaceutical companies to address their enormous research and development (R&D) expenses. In this study, we provide a brief overview of commercial products utilizing modern HT-OoC systems in drug discovery and development. Additionally, we discuss recent trends in R&D aimed at industrialization.
现代药物发现是由制药行业对针对潜在靶点测试不断增加的化合物库的高需求所驱动的。高通量筛选（HTS）的特点是利用机器人液体处理系统、分析技术以及先进的计算和统计方法进行全自动实验，包括最近人工智能的整合。为了顺应这一趋势，开发和实施具有更高预测性和生理相关性的新型高通量筛选平台至关重要。近年来，微生理系统，通常称为芯片器官（OoC）系统，已从理论概念发展成为传统体外和动物模型的有力替代方案。高通量芯片器官（HT-OoC）系统可能代表了制药公司寻求的颠覆性技术，以应对其巨大的研发（R&D）费用。在本研究中，我们简要概述了在药物发现和开发中利用现代高通量芯片器官系统的商业产品。此外，我们还讨论了旨在实现产业化的研发最新趋势。
